Product Details

Auro-Finasteride

Finasteride
5 mg
Tablet

DIN/PIN/NPN

02405814

Manufacturer

Auro Pharma Inc.

Formulary Listing Date

2013-07-30

Unit Price

0.3506

Amount MOH Pays

0.3506

Coverage Status

Limited Use Product Chronic-Use Medication

ODB Formulary Therapeutic Classification

92:00:00 Unclassified Therapeutic Agents

Therapeutic Note

NO

ATC Code

G04CB01

Interchangeable Products

DIN/ PIN/ NPN	Brand name	Unit Price	Amount MOH pays
02322579	Sandoz Finasteride	0.3506	0.3506
02455013	Riva-Finasteride	0.3506	0.3506
02306905	Ratio-Finasteride	0.3506	0.3506
02010909	Proscar	2.4390	0.3506
02310112	PMS-Finasteride	0.3506	0.3506
02348500	Novo-Finasteride	0.3506	0.3506
02389878	Mint-Finasteride	0.3506	0.3506
02357224	Jamp-Finasteride	0.3506	0.3506
02355043	Finasteride Tablets USP	0.3506	0.3506
02447541	Finasteride	0.3506	0.3506
02445077	Finasteride	0.3506	0.3506
02405814	Auro-Finasteride	0.3506	0.3506
02365383	Apo-Finasteride	0.3506	0.3506
02522489	M-Finasteride	0.3506	0.3506

LU Clinical Criteria

LU Code	Auth. Period	Clinical Criteria
384	Indefinite	For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. *Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night.
385	Indefinite	For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. *Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night.

EAP Criteria

NO

Product Monograph